USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ORPHAGEN PHARMACEUTICALS
Address: 11494 Sorrento Valley Road
SAN DIEGO, CA 92121-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,070,132.00 12
SBIR Phase II $961,179.00 1

Award List:

Adrenal Androgen Blockade for Metastic Prostate Cancer

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher
Award Amount: $499,746.00
Abstract:
DESCRIPTION (provided by applicant): Prostate cancer is the second most common cause of cancer death among men in the United States. The first-line therapy for metastatic prostate cancer is suppression of testicular androgen synthesis. Testosterone precursors derived from the adrenal gland, the… More

Novel Drug Target for Bile and Cholesterol Metabolism

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher
Award Amount: $144,158.00
Abstract:
DESCRIPTION (provided by applicant): Regulation of bile acid metabolism is a therapeutic target for treatment of hypercholesterolemia as well as for cholestasis, the pathological buildup of bile in liver. Therapeutic options for direct modulation of hepatic bile formation and transport are limited.… More

Thymocyte Drug Target of Immune Reconstitution

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher
Award Amount: $270,181.00
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of this proposal is to develop the first class of small molecule, orally-bioavailable drugs that increases T cell production from the thymus and enhances immune reconstitution in AIDS and other immunodeficiencies. About 40 million… More

Therapeutic Target for Atherogenic & Metabolic Syndromes

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher
Award Amount: $218,858.00
Abstract:
DESCRIPTION (provided by applicant): The central goal of this project is to identify potent and specific small molecule ligands to the orphan nuclear receptor RORalpha (NR1F1). As a drug target, RORalpha has the potential to address pathological factors in the pre-diabetic metabolic syndrome and in… More

Small Molecule Ligand Discovery for Sleep Cycle Disorders

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher
Award Amount: $460,339.00
Abstract:
DESCRIPTION (provided by applicant): The central circadian regulator of the brain, the suprachiasmatic nucleus (SCN), has been implicated in the pathology of sleep disorders. Deterioration of sleep consolidation, such as inappropriate or fragmented sleep, increases with age or dementia and is… More

Feasibility Study of Novel Drug Target for Multiple Sclerosis

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher
Award Amount: $513,786.00
Abstract:
DESCRIPTION (provided by applicant): A novel class of T helper cell, distinct from TH1 and TH2 cells, has been implicated in the development of murine experimentally-acquired encephalomyelitis (EAE), a model of multiple sclerosis (MS). This effector T cell , termed a TH-17 cell, is characterized by… More

Small molecule target for suppression of autoimmunity in rheumatoid arthritis

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher
Award Amount: $258,166.00
Abstract:
DESCRIPTION (provided by applicant): The pro-inflammatory cytokine IL-17 has been implicated in joint destruction and in the inflammatory pathogenesis of rheumatoid arthritis (RA) in human studies. Targeted deletion or inhibition of IL-17 leads to signific ant reduction in disease severity in animal… More

Small Molecule Inhibitors of Effector Th-17 Cells in Inflammatory Bowel Disease

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher
Award Amount: $266,559.00
Abstract:
DESCRIPTION (provided by applicant): Inflammatory bowel disease (IBD), including Crohn's Disease and ulcerative colitis (UC), is a lifelong T cell- mediated inflammatory condition of the small intestine or colon. The highly proinflammatory cytokine interle ukin-17 (IL-17) is elevated in proportion… More

Novel CNS Target for Sleep-Wake and Psychiatric Disorders

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Scott M. Thacher
Award Amount: $961,179.00
Abstract:
DESCRIPTION (provided by applicant): Circadian regulation of behavioral, metabolic, and endocrine function is a fundamental homeostatic process. Disruption of the circadian clock has been linked to sleep and psychiatric disorders at the genetic and molecul ar level. We initiated a discovery program… More

Inhibitor of Adrenal Steroid Synthesis for Cancer Treatment

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher
Award Amount: $520,358.00
Abstract:
DESCRIPTION (provided by applicant): Orphagen has identified antagonists to an orphan receptor that regulates the major biosynthetic steps of steroid hormone synthesis in the adrenal cortex and gonads. Safe and effective inhibition of adrenal steroid syn thesis has a number of potential… More

A Novel Target for the Treatment of Endometriosis

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul D. Crowe – 619-658-7600
Award Amount: $220,839.00
Abstract:
DESCRIPTION (provided by applicant): Endometriosis is a major cause of severe pelvic pain, pain during menstruation, dyspareunia and infertility in women of child-bearing age with an estimated 22 billion cost of diagnosis and treatment in the U.S. The disease ordinarily regresses after menopause… More

Neural Stem Cell-Selective Drug Target for Small Molecule Therapy of Brain Tumors

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher – 858-481-6191
Award Amount: $250,507.00
Abstract:
DESCRIPTION (provided by applicant) Median survival from time of diagnosis of glioblastoma multiforme (GBM) or stage IV glioma, the most malignant form of brain cancer, is about one year, despite the current aggressive treatment that combines surgery, radiotherapy, chemotherapy, and bevacizumab… More

Selectin targeted ultrasound contrast agents for detection of acute coronary synd

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott M. Thacher – 858-481-6191
Award Amount: $446,635.00
Abstract:
DESCRIPTION (provided by applicant): Retinitis pigmentosa (RP), a hereditary disease of the retina affecting 100,000 Americans, is the major cause of blindness in adults aged 25-60. There is no approved therapy for the disease and gene therapy, while promising, is limited because of the diversity of… More